First Author: T.Wasfy EGYPT
Co Author(s): E. Elgemai
Back to previous
To compare the effect of different available types of anti-VEGF therapy on the regression of stage III retinopathy of prematurity (ROP).
Ophthalmology department, Faculty of medicine, Tanta University
15 neonates with stage III ROP were divided into 3 groups, 5 in each, where the first group was given single injection of bevacizumab, the second was given single injection of ranibizumab and the third one was given single injection of Afilbercept. The 3 groups were followed up for signs of ROP to detect the progression by Retcam at 1st, 3rd and 6th month after injection.
The 3 groups showed marked improvement in all signs of ROP after the injection. This improvement includes absorption of the vitreous haemorrhage, regression of the NVEs, increased area of retinal perfusion and flattening of the ridge between the healthy and the diseased parts of the retina. However, Group 3 (Afilbercept ) showed the best and the most long lasting improvement in all signs of the disease followed by Group 1 (bevacizumab) and lastly Group 2 (ranibizumab)
Early anti-VEGF therapy greatly affects the prognosis of stage III ROP. Afilbercept gives the best and most long lasting effect on the disease followed by bevacizumab and lastly ranibizumab